2008 Presentations

Audio for the 2008 presentations is now available please allow time to load

Click on the following icon to hear the audio for the presentations

Click on the title to view the powerpoint presentations

 

Thursday, March 6, 2008

Clinical Trails In Neurotherapeutics (Full Audio)

	Phases of Therapeutic Development by Virinder Nohria, M.D., Ph.D
	Placebo: Ethics and Alternatives by Samuel Frank, M.D.
	Fundamentals of Clinical Trials Endpoints by Betsy Garofalo M.D.
	Statistical Considerations in Clinical Trials by Susan S. Ellenberg, Ph.D.
	Dose Selection in Pharmaceutical Development by Eliseo Salinas, M.D., Msc
	Clinical Pharmacology in Drug Development by Ramana S. Uppoor, R.Ph., Ph.D.
	Equivalence, Similarity, and Non-Inferiority by Marc K. Walton, M.D., Ph.D.
	Data Safety Monitoring Board by Jennifer Schumi, Ph.D

Seventh Annual Advocacy Forum: Patient-Reported Outcome Data: Will this improve therapeutic Development (Full Audio)

	Regulary and Industry Perspective by Toni Stifano and Chris Leibman
	Investigator Perspective by Robert Griggs, M.D.
	The Importance of Patient-Reported Outcomes ... It's All About the Patients
	NIH's Patient-Reported Outcomes Measurement Information Systems (PROMIS)

Roundtable Discussion - Why Things Are The Way They Are- Monitoring, Data Chain Of Custody, Crfs And Other Mysteries Revealed by Christopher C. Gallen, M.D., Ph.D.

Dinner Symposium: Post-Marketing Surveillance

	Is FDA Failing Us or are we Failing FDA? by Jonathan C. Javitt, M.D.,M.P.H
	Magic Bullets and Miracle Cures? The Reality Of Post-Marketing Surveillance  by Janice K. Bush, M.D.
	Post-Marketing Surveillance: One Division Director’s View by Russell Katz, M.D

Friday, March 7, 2008

Symposium: Clinical Trails, Treatments and Tribulations in Neuroprotection and Disease Modification (Full audio)

	Clinical Trials in Acute Stroke by Sean Savitz, M.D.
	Clinical Trials In Alzheimer’s Disease by Paul S. Aisen, M.D.
	Clinical Trials in ALS by Merit E. Cudkowicz, M.D.
	Enhancing Recover after Acute Ischemia, Steven C. Cramer, M.D.
	Advances In ALS Therapy: A Brave New World by Preclinical Studies - Robert Brown, Jeffrey Rothstein, Tim Miller, Don Cleveland, Bob Ferrante, Terry Heiman Patterson & Clinical Studies - Jeremy Shefner, David Schoenfeld , Tim Miller, Northeast ALS Consortium

 

General Session: How to Measure Long-Term Outcomes

	Measuring Long-Term Efficacy In Epilepsy Trials by Jacqueline A. French M.D.
	Long-Term Outcomes after Acute Stroke Treatment by Larry B. Goldstein, M.D.
	Long Term Outcomes In Alzheimer’s Disease By Eric Siemers, M.D.
	Neurorehabilitation Long-Term Outcomes by George F. Wittenberg, M.D., Ph.D

Saturday March 8, 2008

Symposium: The Science of Multi-potential Therapies - Which Indication Do You Pursue?

	Putative Multimodal Neuroprotective, Neurorestorative and Symptomatic Drugs For Neurodegenerative Disorders  By Moussa. B.H. Youdim
	Botulinum Toxin's Serendipitous Targets by The Science of Multi-Potential Therapies By Clare J. Fowler
	Multi-Potential Therapies Which Indication Do You Go After? - Antiseizure Drugs As Neuromodulators By Roy Twyman
	Clinical Development of Marketed Drugs for New Uses by Russell Katz, M.D.